Results 221 to 230 of about 15,183,159 (329)

Toward international collaboration in allergy care - WAO White Book on Allergy 2026 - Introduction. [PDF]

World Allergy Organ J
Al-Ahmad M, Ansotegui IJ, Ebisawa M, Fiocchi A, González-Díaz SN, Martin BL, Wing-Kin Wong G, Morais-Almeida M.   +7 more
europepmc   +1 more source

Orchids at the Intersection of Climate, Biotic Interactions, and Evolutionary Dynamics. [PDF]

Plants (Basel)
Štípková Z, Djordjević V.
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Special issue: Critical Latinx indigeneities

, 2017
Maylei Blackwell, Floridalma Boj Lopez, Luis Urrieta   +2 more
semanticscholar   +1 more source

Superconducting artificial neural networks and quantum circuits. [PDF]

Beilstein J Nanotechnol
Sidorenko AS.
europepmc   +1 more source

Institutional Entrepreneurship as Embedded Agency: An Introduction to the Special Issue

, 2007
R. Garud, C. Hardy, S. Maguire
semanticscholar   +1 more source

In This Issue

Delaware Journal of Public Health
Khan, Omar A., Smith, Katherine
openaire   +3 more sources

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Download Complete Issue: 07 (9MB)

, 1989
Issue, Complete
core   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source